[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369594-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369594-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","innovative-technologies-and-their-clinical-prospects-for-early-lung-cancer-screening","Innovative technologies and their clinical prospects for early lung cancer screening","","Lung cancer remains the leading cause of cancer-related death worldwide, driven by insufficient early-stage screening options. Imaging such as low-dose CT introduces radiation risk, while biopsies may cause complications; conventional serum tumor markers also lack diagnostic specificity. This systematic review evaluates limitations of conventional screening and explores liquid biopsy breakthroughs. It assesses how artificial intelligence can enhance early detection and supports evidence-based development of an optimized screening framework.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/innovative-technologies-and-their-clinical-prospects-for-early-lung-cancer-screening/369594/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/innovative-technologies-and-their-clinical-prospects-for-early-lung-cancer-screening/369594.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early lung cancer screening still a major clinical challenge?","Question",{"text":63,"@type":64},"Early-stage detection is difficult because effective screening approaches are limited. Low-dose CT carries radiation risk, biopsies can lead to complications, and serum tumor markers often lack diagnostic specificity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What does the systematic review aim to evaluate?",{"text":68,"@type":64},"It evaluates the limitations of conventional screening methods, searches for breakthroughs in liquid biopsy for early lung cancer detection, and assesses the potential value of artificial intelligence.",{"name":70,"@type":61,"acceptedAnswer":71},"What conclusions does the review draw about liquid biopsy and AI-assisted diagnostics?",{"text":72,"@type":64},"Novel liquid biopsy techniques are non-invasive and show superior diagnostic efficacy. AI-assisted diagnostics can further enhance diagnostic accuracy, supporting a comprehensive screening workflow.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369594,1790491795,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Clinical and Experimental Medicine (2025) 25:212 [https://doi.org/10.1007/s10238-025-01752-6](https://doi.org/10.1007/s10238-025-01752-6)  \nInnovative technologies and their clinical prospects for early lung cancer screening  \nZisu Deng1,2 · Xiaocao Ma3 · Shubiao Zou1 · Liling Tan1 · Tingting Miao1  \nReceived: 6 May 2025 / Accepted: 23 May 2025 / Published online: 18 June 2025 © The Author(s) 2025  \nAbstract  \nBackground Lung cancer remains the leading cause of cancer-related mortality worldwide, due to lacking effective earlystage screening approaches. Imaging, such as low-dose CT, poses radiation risk, and biopsies can induce some complications. Additionally, traditional serum tumor markers lack diagnostic specificity. This highlights the urgent need for precise and non-invasive early detection techniques.  \nPurpose This systematic review aims to evaluate the limitations of conventional screening methods (imaging/biopsy/tumor markers), seek breakthroughs in liquid biopsy for early lung cancer detection, and assess the potential value of Artificial Intelligence (AI), thereby providing evidence-based insights for establishing an optimal screening framework.  \nMethods We systematically searched the PubMed database for the literature published up to May 2025. Key words include“Artificial Intelligence”, \"Early Lung cancer screening”,“Imaging examination”,“Innovative technologies”,“Liquid biopsy”, and “Puncture biopsy”. Our inclusion criteria focused on studies about traditional and innovative screening methods, with an emphasis on original research concerning diagnostic performance or high-quality reviews. This approach helps identify critical studies in early lung cancer screening.  \nConclusions Novel liquid biopsy techniques are non-invasive and have superior diagnostic efficacy. AI-assisted diagnostics further enhance accuracy. We propose three development directions: establishing risk-based liquid biopsy screening protocols, developing a stepwise \"imaging-AI-liquid biopsy\" diagnostic workflow, and creating standardized biomarker panel testing solutions. Integrating traditional methodologies, novel liquid biopsies, and AI to establish a comprehensive early lung cancer screening model is important. These innovative strategies aim to significantly increase early detection rates, substantially enhancing lung cancer control. This review provides both theoretical guidance for clinical practice and future research.  \nKeywords Artificial intelligence · Early lung cancer screening · Imaging examination · Innovative technologies · Liquid biopsy · Puncture biopsy  \nAbbreviations  \nAFB Autofluorescence Bronchoscopy  \nAFP Alpha-Fetoprotein  \n* Tingting Miao [Tingtingmiao888@163.com](Tingtingmiao888@163.com)  \n1 Department of Nuclear Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China  \n2 Department of Preventive Medicine, School of Public Health, Nanchang University, Nanchang, Jiangxi, China  \n3 Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China  \nAI CA-199 CAD CAGE CEAcfDNACH3  \ncircRNAs CpG  \nCTCs  \nCXRCYFRA 21-1 DNMT  \nEMT  \nFDG  \nGAGE7  \nArtificial Intelligence Carbohydrate Antigen-199  \nComputer-Aided Diagnosis Cancer-Associated Gene Carcinoembryonic Antigen Cell-Free DNA  \nMethyl Group  \nCircular RNAs Cytosine–Phosphate–Guanine Circulating Tumor Cells  \nChest X-Ray Screening Cytokeratin-19 Fragment Antigen 21-1 DNA Methyltransferase Epithelial–Mesenchymal Transition Fluorodeoxyglucose  \nG Antigen 7  \nGBU4-5 Globoside Binding Unit 4-5  \nMAGE A1 Melanoma Antigen A1  \nmiRNAs MicroRNAs  \nIARC International Agency for Research on  \nCancer LncRNAs Long Non-Coding RNAs  \nLCCDE Lung Cancer Cells-Derived Exosomes  \nLDCT Low-Dose Computed Tomography  \nLUAD Lung Adenocarcinoma","cbCaidh3iv8qlqte","https://ap.wps.com/l/cbCaidh3iv8qlqte","pdf",1154439,16,"English","# Abstract\n## Background\n## Purpose\n## Methods\n## Conclusions\n# Introduction\n## Epidemiology and survival challenges","[{\"question\":\"Why is early lung cancer screening still a major clinical challenge?\",\"answer\":\"Early-stage detection is difficult because effective screening approaches are limited. Low-dose CT carries radiation risk, biopsies can lead to complications, and serum tumor markers often lack diagnostic specificity.\"},{\"question\":\"What does the systematic review aim to evaluate?\",\"answer\":\"It evaluates the limitations of conventional screening methods, searches for breakthroughs in liquid biopsy for early lung cancer detection, and assesses the potential value of artificial intelligence.\"},{\"question\":\"What conclusions does the review draw about liquid biopsy and AI-assisted diagnostics?\",\"answer\":\"Novel liquid biopsy techniques are non-invasive and show superior diagnostic efficacy. AI-assisted diagnostics can further enhance diagnostic accuracy, supporting a comprehensive screening workflow.\"}]","Innovative technologies and their clinical prospects for early lung cancer screening | PDF",1790183600,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e342ce4480f32bd2e70614099e754bd.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b03c60e492cb098e2303f0d4cd315639.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3915bac657be9823a04a92a643367c65.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da786fe7a7b56f96c9b47bba06163683.webp",980,1301]